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Aicardi-Goutières syndrome (AGS) is a rare inflammatory encephalopathy mimicking in utero ac- 
quired viral infection. Cardinal findings comprise leukodystrophy, basal ganglia calcifications and 
cerebral atrophy along with cerebrospinal fluid lymphocytosis and elevated interferon-α. In the 
majority of cases AGS is inherited as an autosomal recessive trait and caused by mutations in six 
genes including RNASEH2A, RNASEH2B, RNASEH2C, TREX1, SAMHD1 and ADAR1, all of which encode 
enzymes acting on nucleic acid species. Most patients present with first neurological signs in early 
infancy and experience severe global developmental delay. Here, we report on the unusual diver- 
gent phenotype of two siblings who both carry the most frequent AGS causing p.A177T (c.529G > A) 
RNASEH2B mutation in the homozygous state. While one sibling showed a typical AGS presentation 
with early onset and severe statomotor and mental impairment, the older sibling was intellec- 
tually completely normal. She was only diagnosed because of mild spasticity of the legs and sero- 
logical signs of autoimmunity. These findings highlight the phenotypic variability of AGS and sug- 
gest that AGS may be underdiagnosed among children with mild cerebral palsy. 
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The classical presentation of AGS consists of an inflammatory encephalopathy characterized by dystonic move- 
ments, irritability and/or seizures as well as sterile pyrexic episodes [1]. Parents of affected children typically 
describe inconsolable crying and insomnia [2]. Some patients present with hepatomegaly and thrombocytopenia 
[3]. In addition, cutaneous inflammatory lesions at acral locations, also referred to as chilblain lesions, represent 
a highly distinctive feature of AGS [4]. The lesions are typically cold-induced and may occur later during the 
course of the disease. In most cases the symptoms begin during the first months of life following a period of 
normal development. Neuroimaging findings include basal ganglia calcifications, white matter disease and 
atrophy leading to progressive microcephaly [1]. In addition, lymphocytosis and raised interferon-α levels in 
CSF are commonly observed during the early encephalitic phase [5]. The disease usually results in profound 
developmental delay. 
All genes currently known to cause AGS, namely TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 
and ADAR1, encode enzymes that process nucleic acid species including DNA, RNA or DNA precursors [6]. 
Indeed, the elucidation of the genetic causes of AGS has provided novel insight into the role of the intracellular 
nucleic acid metabolism for the maintenance of immune tolerance. Recognition of foreign nucleic acids of viral 
origin by innate immune receptors is an integral aspect of the immune defense against pathogens. The limited 
capacity of these immune receptors to distinguish between endogenous and foreign nucleic acids requires ap- 
propriate mechanisms to dispose of nucleic acid metabolites arising during cell metabolism. Mutations in the 
AGS-causing genes are thought to result in the inability to dispose of such endogenous nucleic acids. As a con- 
sequence, these nucleic acid metabolites accumulate and initiate an interferon-α-mediated innate immune re-
sponse leading to inflammation and autoimmunity [6]. 
2. Case Reports 
2.1. Patient 1 
Patient 1 is the 4-year-old forth child of a consanguineous Moroccan couple. He was born at 31 weeks of gesta- 
tion due to preterm labor following an uneventful pregnancy with a normal birth weight (50th percentile) and a 
normal head circumference (50th percentile) for his gestational age. Post-partum a mild intracranial hemorrhage 
was noticed which resolved within 2 months. His newborn screening and newborn hearing tests were unre- 
markable. He developed normally until the corrected age of 11 months. At this time the parents noted increased 
irritability, jerky movements and an abrupt regression of developmental milestones. He had previously reached 
full head control, learned to sit unsupported and was able to raise objects. Upon examination at that age his 
weight, length and head circumference were at the 10th percentile. His head circumference further declined and 
was at the 1st percentile at 4 years of age. Neurologically he demonstrated signs of global developmental delay, 
truncal hypotonia and reappearance of primitive reflexes. Magnetic resonance (MR) imaging performed at the 
age of 14 and 23 months, respectively, revealed ventricular enlargement due to cortical atrophy with symmetric- 
al hyper-intensive (T2w) signals of the white matter and progressive demyelination of previously myelinated re- 
gions including the posterior limb of the capsula interna, cerebellum and subcortical regions (Figure 1). A 
cranial computer tomography to look for calcifications was not undertaken. A lumbar puncture revealed mild 
pleocytosis, raised levels of neopterine and interferon-a (6 IU/ml) in the cerebrospinal fluid (CSF). In addition, 
the child experienced frequent febrile episodes that led to several medical consultations. However, all laboratory 
findings were unremarkable and no infectious cause could be identified. Further diagnostic work-up revealed no 
evidence for metabolic or endocrinologic disorders. An immunofluorescence screening test (IFT) demonstrated 
an anti-nuclear antibody (ANA) titer of 1:160 with a dense fine speckled pattern. Genetic testing revealed ho- 
mozygosity for the common AGS-associated p.A177T (c.529G > A) mutation of the RNASEH2B gene. 
2.2. Patient 2 
Patient 2 is the 20-year-old sister of patient 1 and the oldest sibling of the family. Patient 2 was born at term after 
an uncomplicated pregnancy with weight, length and head circumference within normal range. She achieved all 
developmental milestones adequately until the age of 21 months. At this time, following intramuscular adminis- 
tration of the MMR (measles, mumps, rubella) vaccine into the thigh, the parents noted a weakness of the ipsi- 
lateral leg. The reduction in muscle strength further developed into a partial spastic paralysis of both legs.  





Figure 1. Bilateral periventricular hyperintensities on T2-weighted 
axial MR imaging at 14 months (b) and 23 months of age (c) indi-
cating pathological white matter changes of previously physiolog-
ically myelinated areas at 9 months of age (a), particularly affect-
ing the fronto- and occipito-temporal cortex. In addition, enlarge-
ment of the ventricles is noted. 
 
Except for a temporary delay in gross motor skills due to the spastic paraparesis, the patient developed normally. 
Her language skills, intellectual and cognitive abilities were within normal range. Owing to extensive physio- 
therapy and orthopedic surgery she gradually learned to walk again. She successfully completed secondary 
school and has received a driver’s license. The underlying cause of the mild spastic palsy could not be explained 
at that time. MR imaging of the brain and spine, somatosensory evoked potentials as well as extensive metabolic, 
infectious and endocrinologic laboratory studies were unremarkable. An IFT performed at 20 years of age 
showed an ANA titer of 1:320 with centromere pattern. Upon further serologic examination she tested positive 
for auto-antibodies against U1-RNP/O (32.2 U/ml, positive) and CENP-B (15 U/ml; weakly positive). Genetic 
testing confirmed that patient 2 was also homozygous for the same RNASEH2B mutation found in her affected 
brother. Her two 11- and 16-year-old sisters were healthy and did not carry the A177T RNASEH2B mutation. 
Both parents were heterozygous carriers. 
3. Discussion 
The clinical findings of patient 1 who presented with an early-onset non-infectious inflammatory encephalopa- 
thy featuring a raised interferon-α level in CSF represent the typical findings seen in patients with AGS. The 
fever episodes observed during the sub-acute onset of the disease have also commonly been reported in AGS 
patients and are thought to reflect the early inflammatory phase of the encephalopathy [2] [3]. This phase is fol- 
lowed by the appearance of progressive neurodegenerative signs including loss of skills, psychomotor retarda- 
tion and microcephaly [1] [3]. Indeed, the diagnosis of AGS in this patient could be confirmed by genetic testing. 
The identified A177T mutation in the RNASEH2B gene represents the single most common mutation found in 
AGS patients to date and has been found both in the homozygous or compound heterozygous state across dif- 
ferent ethnic populations suggesting that it represents a mutation hot spot rather than a founder mutation [2] [3] 
[7]. 
Previous studies have extended the phenotypic spectrum of the disorder originally described by Aicardi and 
Goutières [1]. In addition to chilblain lesions, AGS patients commonly develop signs of systemic autoimmunity 
including hematopoietic abnormalities, antinuclear antibodies or other autoantibodies [2] [4]. Autoimmune phe- 
nomena may be present early on, but often appear later during the course of the disease. RNASEH2B encodes 
one of the three subunits of ribonuclease 2, which degrades the RNA moiety of RNA:DNA hybrids or removes 
single ribonucleotides embedded within a DNA duplex [7]. Indeed, chronic activation of the antiviral interferon 
axis induced by immune recognition of unmetabolized endogenous nucleic acids is thought to result in inflam- 
mation and autoimmunity [6]. 
While the breadth of the clinical presentation of AGS is only emerging, a correlation of certain AGS pheno- 
types with mutations in distinct AGS genes has previously been recognized. Thus, a severe AGS presentation 
with neonatal onset or even intrauterine brain calcifications is associated with high morbidity and mortality and 
is more commonly seen in patients carrying TREX1 mutations [3]. In contrast, a later onset occurring after sev- 
eral months of normal development or beyond the first year of life is associated with a lower mortality rate and 
more frequently due to RNASEH2B mutations [2] [3]. While cutaneous chilblain lesions have been observed in 
(a) (b) (c)




AGS patients harboring mutations in any of the known AGS genes, arthritis or arthropathy has so far only been 
described in patients with SAMHD1 mutations [8] [9]. 
The here reported siblings who both carry the same homozygous RNASEH2B mutation show an extraordinary 
intrafamilial phenotypic variability with one sibling being severely affected and the other showing only mild 
neurologic impairment with normal intelligence. To our knowledge there is only one report of a comparable 
intrafamilial variable phenotype observed in a family carrying a mutation in the RNASEH2C gene which en- 
codes another subunit of ribonuclease H2 [10]. While the phenotypic variability may be solely genetically de- 
termined, our observations also raise the question of whether there are yet unidentified non-genetic trigger fac- 
tors that could impact disease initiation and outcome. Moreover, these findings suggest that the prevalence of 
AGS may be much higher than previously estimated. Thus, AGS should be considered in any patient with an 
unexplained mild form of cerebral palsy. 
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